XBiotech Inc. (XBIT)
NASDAQ: XBIT · IEX Real-Time Price · USD
8.02
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
8.20
+0.18 (2.24%)
After-hours: May 3, 2024, 7:58 PM EDT
XBiotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
82
Market Cap
258.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 4.01M | -14.38M | -78.20% |
Dec 31, 2021 | 18.39M | -25.60M | -58.19% |
Dec 31, 2020 | 44.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 512.35M |
Coherus BioSciences | 257.24M |
Foghorn Therapeutics | 34.16M |
Werewolf Therapeutics | 16.22M |
Adlai Nortye | 5.00M |
XBIT News
- 4 months ago - XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus - GlobeNewsWire
- 6 months ago - Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - GlobeNewsWire
- 7 months ago - XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire
- 8 months ago - XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer - GlobeNewsWire
- 9 months ago - XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - GlobeNewsWire
- 1 year ago - FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients - GlobeNewsWire
- 1 year ago - XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares - GlobeNewsWire
- 1 year ago - XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire